These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 8390252)

  • 1. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
    Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
    Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct inhibition by non-peptide and peptide arginine vasopressin antagonists of vasopressin-induced activation of mitogen-activated protein kinase in cultured rat vascular smooth muscle cells.
    Okada K; Sasaki R; Ishikawa S; Saito T
    Biochem Biophys Res Commun; 1994 Apr; 200(2):1155-60. PubMed ID: 8179597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking effects of V1 (OPC-21268) and V2 (OPC-31260) antagonists on the negative inotropic response to vasopressin in isolated dog heart preparations.
    Furukawa Y; Takayama S; Ren LM; Sawaki S; Inoue Y; Chiba S
    J Pharmacol Exp Ther; 1992 Nov; 263(2):627-31. PubMed ID: 1331408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a new V1 antagonist (OPC-21268) on vascular action of vasopressin in cultured rat vascular smooth muscle cells.
    Okada K; Ishikawa S; Saito T
    Biochem Biophys Res Commun; 1991 Jul; 178(2):707-12. PubMed ID: 1650196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological evaluation of d(CH2)5Tyr(Me)AVP as an antagonist of vasopressin-induced contraction of the isolated rat caudal artery.
    Clineschmidt BV; Lis EV
    Arch Int Pharmacodyn Ther; 1986 Nov; 284(1):72-84. PubMed ID: 2950833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
    Hinojosa C; Haywood JR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):492-6. PubMed ID: 2874211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin.
    Manning M; Stoev S; Bankowski K; Misicka A; Lammek B; Wo NC; Sawyer WH
    J Med Chem; 1992 Jan; 35(2):382-8. PubMed ID: 1531076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.
    Tahara A; Tsukada J; Tomura Y; Suzuki T; Yatsu T; Shibasaki M
    Vascul Pharmacol; 2007 Jun; 46(6):463-9. PubMed ID: 17395547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
    Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.
    Bernat A; Hoffmann P; Dumas A; Serradeil-le Gal C; Raufaste D; Herbert JM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):597-602. PubMed ID: 9262320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells.
    Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P
    Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increases in cellular sodium concentration by arginine vasopressin and endothelin in cultured rat glomerular mesangial cells.
    Ishikawa S; Okada K; Saito T
    Endocrinology; 1992 Sep; 131(3):1429-35. PubMed ID: 1505472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of arginine vasopressin on differentiation of cardiac fibroblasts into myofibroblasts.
    Yan-Hong F; Hui D; Qing P; Lei S; Hai-Chang W; Wei Z; Yan-Jie C
    J Cardiovasc Pharmacol; 2010 May; 55(5):489-95. PubMed ID: 20164786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct.
    Yoshitomi K; Naruse M; Hanaoka K; Yamamura Y; Imai M; Kurokawa K
    Kidney Int Suppl; 1996 Jun; 55():S177-82. PubMed ID: 8743549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of receptors mediating contraction of the rat isolated small mesenteric artery and aorta to arginine vasopressin and oxytocin.
    Stam WB; Van der Graaf PH; Saxena PR
    Br J Pharmacol; 1998 Oct; 125(4):865-73. PubMed ID: 9831926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Through V2, not V1 receptor relating to endogenous opiate peptides, arginine vasopressin in periaqueductal gray regulates antinociception in the rat.
    Yang J; Chen JM; Liu WY; Song CY; Lin BC
    Regul Pept; 2006 Dec; 137(3):156-61. PubMed ID: 17011056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a novel non-peptide vasopressin V1 receptor antagonist (OPC-21268) in the rat.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    J Endocrinol; 1993 Aug; 138(2):259-66. PubMed ID: 8228734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of amiloride analogues on AVP binding and activation of V1-receptor-expressing cells.
    Thibonnier M; Bayer AL; Simonson MS; Douglas JG
    Am J Physiol; 1992 Jan; 262(1 Pt 1):E76-86. PubMed ID: 1733254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of an orally active vasopressin V1 receptor antagonist.
    Burrell LM; Phillips PA; Stephenson J; Risvanis J; Hutchins AM; Johnston CI
    Clin Exp Pharmacol Physiol; 1993 May; 20(5):388-91. PubMed ID: 8391950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.